Model systems of human papillomavirus-associated disease

Journal of Pathology

Volumn 238, Issue 2, 2016, Pages 166-179

  Doorbar, John ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

animal models; epithelium; HPV; organotypic rafts; papillomaviruses

Indexed keywords

WART VIRUS VACCINE;

CANCER GROWTH; DISEASE ASSOCIATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; TISSUE CULTURE; TRANSGENIC ANIMAL; UTERINE CERVIX CANCER; VIRAL TROPISM; ANIMAL; CARCINOGENESIS; CELL CULTURE TECHNIQUE; COMPLICATION; DISEASE COURSE; DISEASE MODEL; FORECASTING; MOUSE; NEOPLASM; PAPILLOMAVIRUS INFECTIONS; RABBIT; RISK FACTOR; TUMOR VIRUS INFECTIONS; VIROLOGY;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CARCINOGENESIS; CELL CULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FORECASTING; HUMANS; IN VITRO TECHNIQUES; MICE; NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RABBITS; RISK FACTORS; TUMOR VIRUS INFECTIONS;

EID: 84951325997     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4656     Document Type: Review

References (135)

1. Doorbar J, Quint W, Banks L, et al., The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 (suppl 5): F55-70.
2. Doorbar J, Egawa N, Griffin H, et al., Human papillomavirus molecular biology and disease association. Rev Med Virol 2015; 25 (suppl 1): 2-23.
3. zur Hausen H., Papillomaviruses in the causation of human cancers-a brief historical account. Virology 2009; 384: 260-265.
4. Gottschling M, Goker M, Stamatakis A, et al., Quantifying the phylodynamic forces driving papillomavirus evolution. Mol Biol Evolut 2011; 28: 2101-2113.
5. Stanley MA,. Establishing HPV-containing keratinocyte cell lines from tissue biopsies. Methods Mol Med 2005; 119: 129-139.
6. Lambert PF, Ozbun MA, Collins A, et al., Using an immortalized cell line to study the HPV life cycle in organotypic 'raft' cultures. Methods Mol Med 2005; 119: 141-155.
7. McLaughlin-Drubin ME, Meyers C,. Propagation of infectious, high-risk HPV in organotypic 'raft' culture. Methods Mol Med 2005; 119: 171-186.
8. de Martel C, Ferlay J, Franceschi S, et al., Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-615.
9. Forman D, de Martel C, Lacey CJ, et al., Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 (suppl 5): F12-23.
10. Moscicki AB, Schiffman M, Burchell A, et al., Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30 (suppl 5): F24-33.
11. Roman A, Munger K,. The papillomavirus E7 proteins. Virology 2013; 445: 138-168.
12. Vande Pol SB, Klingelhutz AJ,. Papillomavirus E6 oncoproteins. Virology 2013; 445: 115-137.
13. Ernani V, Saba NF,. Oral cavity cancer: risk factors, pathology and management. Oncology 2015; 89: 187-195.
14. Egawa N, Egawa K, Griffin H, et al., Human papillomaviruses: epithelial tropisms, and the development of neoplasia. Viruses 2015; 7: 3863-3890.
15. Westra WH,. The morphologic profile of HPV-related head and neck squamous carcinoma: implications for diagnosis, prognosis, and clinical management. Head Neck Pathol 2012; 6 (suppl 1): S48-54.
16. Isaacson Wechsler E, Wang Q, Roberts I, et al., Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression. J Virol 2012; 86: 6358-6364.
17. Mirabello L, Frimer M, Harari A, et al., HPV16 methyl-haplotypes determined by a novel next-generation sequencing method are associated with cervical precancer. Int J Cancer 2015; 136: E146-153.
18. Smith BC, McAndrew T, Chen Z, et al., The cervical microbiome over 7 years and a comparison of methodologies for its characterization. PLoS One 2012; 7: e40425.
19. Chen Z, Schiffman M, Herrero R, et al., Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One 6: e20183.
20. Campo MS,. Bovine papillomavirus and cancer. Vet J 1997; 154: 175-188.
21. Munday JS,. Bovine and human papillomaviruses: a comparative review. Vet Pathol 2014; 51: 1063-1075.
22. Marchetti B, Gault EA, Cortese MS, et al., Bovine papillomavirus type 1 oncoprotein E5 inhibits equine MHC class I and interacts with equine MHC I heavy chain. J Gen Virol 2009; 90: 2865-2870.
23. Moody CA, Laimins LA,. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10: 550-560.
24. Bonnez W,. The HPV xenograft severe combined immunodeficiency mouse model. Methods Mol Med 2005; 119: 203-216.
25. Bonnez W, Darin C, Borkhuis C, et al., Isolation and propogation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse. J Virol 1998; 72: 5256-5261.
26. Stoler MH, Whitbeck SM, Wolinsky SM, et al., Infectious cycle of human papillomavirus type 11 in human foreskin xenografts in nude mice. J Virol 1990; 64: 3310-3318.
27. Kreider JW, Patrick SD, Cladel NM, et al., Experimental infection with human papillomavirus type 1 of human hand and foot skin. Virology 1990; 177: 415-417.
28. Meyers C, Frattini MG, Hudson JB, et al., Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992; 257: 971-973.
29. Dollard SC, Wilson JL, Demeter LM, et al., Production of human papillomavirus and modulation of the infectious program in epithelial raft culture. Genes Dev 1992; 6: 1131-1142.
30. Meyers C, Laimins LA,. In vitro systems for the study and propagation of human papillomaviruses. Curr Top Microbiol Immunol 1994; 186: 199-215.
31. Flores ER, Allen-Hoffmann BL, Lee D, et al., Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology 1999; 262: 344-354.
32. Fang L, Meyers C, Budgeon LR, et al., Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures. Virology 2006; 347: 28-35.
33. Wang HK, Duffy AA, Broker TR, et al., Robust production and passaging of infectious HPV in squamous epithelium of primary human keratinocytes. Genes Dev 2009; 23: 181-194.
34. Chow LT, Duffy AA, Wang HK, et al., A highly efficient system to produce infectious human papillomavirus: elucidation of natural virus-host interactions. Cell Cycle 2009; 8: 1319-1323.
35. Allen-Hoffmann BL, Schlosser SJ, Ivarie CA, et al., Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. J Invest Dermatol 2000; 114: 444-455.
36. Griffin H, Wu Z, Marnane R, et al., E4 antibodies facilitate detection and type-assignment of active HPV infection in cervical disease. PLoS One 2012; 7: e49974.
37. Fang L, Budgeon LR, Doorbar J, et al., The human papillomavirus type 11 E1/\E4 protein is not essential for viral genome amplification. Virology 2006; 351: 271-279.
38. Stanley MA, Browne HM, Appleby M, et al., Properties of a non-tumorigenic human cervical keratinocyte cell line. Int J Cancer 1989; 43: 672-676.
39. Sterling J, Stanley M, Gatward G, et al., Production of human papillomavirus type 16 virions in a keratinocyte cell line. J Virol 1990; 64: 6305-6307.
40. Hummel M, Hudson JB, Laimins LA,. Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes. J Virol 1992; 66: 6070-6080.
41. De Geest K, Turyk ME, Hosken MI, et al., Growth and differentiation of human papillomavirus type 31b positive human cervical cell lines. Gynecol Oncol 1993; 49: 303-310.
42. Gray E, Pett MR, Ward D, et al., In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis. Cancer Res 2010; 70: 4081-4091.
43. Dall KL, Scarpini CG, Roberts I, et al., Characterization of naturally occurring HPV16 integration sites isolated from cervical keratinocytes under noncompetitive conditions. Cancer Res 2008; 68: 8249-8259.
44. Stanley MA, Pett MR, Coleman N,. HPV: from infection to cancer. Biochem Soc Trans 2007; 35: 1456-1460.
45. McLaughlin-Drubin ME, Bromberg-White JL, Meyers C,. The role of the human papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. Virology 2005; 338: 61-68.
46. Flores ER, Allen-Hoffmann BL, Lee D, et al., The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol 2000; 15: 6622-6631.
47. Moody CA, Fradet-Turcotte A, Archambault J, et al., Human papillomaviruses activate caspases upon epithelial differentiation to induce viral genome amplification. Proc Natl Acad Sci USA 2007; 104: 19541-19546.
48. Spurgeon ME, Lambert PF,. Merkel cell polyomavirus: a newly discovered human virus with oncogenic potential. Virology 2013; 435: 118-130.
49. Oh ST, Longworth MS, Laimins LA,. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. J Virol 2004; 78: 2620-2626.
50. Thomas JT, Oh ST, Terhune SS, et al., Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. J Virol 2001; 75: 7564-7571.
51. Nasseri M, Hirochika R, Broker TR, et al., A human papillomavirus type 11 transcript encoding an E1-E4 protein. Virology 1987; 159: 433-439.
52. Rotenberg MO, Chow LT, Broker TR,. Characterization of rare human papillomavirus type 11 mRNAs coding for regulatory and structural proteins, using the polymerase chain reaction. Virology 1989; 172: 489-497.
53. Christensen ND, Koltun WA, Cladel NM, et al., Coinfection of human foreskin fragments with multiple human papillomavirus types (HPV-11, -40 and -LVX82/MM7) produces regionally separate HPV infections within the same athymic mouse xenograft. J Virol 1997; 71: 7337-7344.
54. Dollard SC, Chow LT, Kreider JW, et al., Characterization of an HPV type 11 isolate propagated in human foreskin implants in nude mice. Virology 1989; 1989: 294-297.
55. Kreider JW, Howett MK, Leure-Dupree EE, et al., Laboratory production in vivo of infectious human papillomavirus type 11 from condylomata accuminata. J Virol 1987; 61: 590-593.
56. Christensen ND, Cladel NM, Reed CA, et al., Laboratory production of infectious stocks of rabbit oral papillomavirus. J Gen Virol 1996; 77: 1793-1798.
57. Quint KD, Genders RE, de Koning MN, et al., Human β-papillomavirus infection and keratinocyte carcinomas. J Pathol 2015; 235: 342-354.
58. Jackson S, Storey A,. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene 2000; 19: 592-598.
59. Akgul B, Garcia-Escudero R, Ghali L, et al., The E7 protein of cutaneous human papillomavirus type 8 causes invasion of human keratinocytes into the dermis in organotypic cultures of skin. Cancer Res 2005; 65: 2216-2223.
60. Akgul B, Bostanci N, Westphal K, et al., Human papillomavirus 5 and 8 E6 downregulate interleukin-8 secretion in primary human keratinocytes. J Gen Virol 2010; 91: 888-892.
61. Hufbauer M, Biddle A, Borgogna C, et al., Expression of β-papillomavirus oncogenes increases the number of keratinocytes with stem cell-like properties. J Virol 2013; 87: 12158-12165.
62. Westphal K, Akgul B, Storey A, et al., Cutaneous human papillomavirus E7 type-specific effects on differentiation and proliferation of organotypic skin cultures. Cell Oncol 2009; 31: 213-226.
63. Akgul B, Ghali L, Davies D, et al., HPV8 early genes modulate differentiation and cell cycle of primary human adult keratinocytes. Exp Dermatol 2007; 16: 590-599.
64. Schaper ID, Marcuzzi GP, Weissenborn SJ, et al., Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res 2005; 65: 1394-1400.
65. Brake T, Lambert PF,. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci USA 2005; 102: 2490-2495.
66. Schaeffer AJ, Nguyen M, Liem A, et al., E6 and E7 oncoproteins induce distinct patterns of chromosomal aneuploidy in skin tumors from transgenic mice. Cancer Res 2004; 64: 538-546.
67. Riley RR, Duensing S, Brake T, et al., Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 2003; 63: 4862-4871.
68. Song S, Pitot HC, Lambert PF,. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J Virol 1999; 73: 5887-5893.
69. Hilditch-Maguire PA, Lieppe DM, West D, et al., T cell-mediated and non-specific inflammatory mechanisms contribute to the skin pathology of HPV 16 E6E7 transgenic mice. Intervirology 1999; 42: 43-50.
70. Griep AE, Krawcek J, Lee D, et al., Multiple genetic loci modify risk for retinoblastoma in transgenic mice. Invest Ophthalmol Vis Sci 1998; 39: 2723-2732.
71. Herber R, Liem A, Pitot H, et al., Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol 1996; 70: 1873-1881.
72. Dong W, Kloz U, Accardi R, et al., Skin hyperproliferation and susceptibility to chemical carcinogenesis in transgenic mice expressing E6 and E7 of human papillomavirus type 38. J Virol 2005; 79: 14899-14908.
73. Michel A, Kopp-Schneider A, Zentgraf H, et al., E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hr1 transgenic mice. J Virol 2006; 80: 11153-11164.
74. Viarisio D, Mueller-Decker K, Kloz U, et al., E6 and E7 from β-HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog 2011; 7: e1002125.
75. Breitburd F, Kirnbauer R, Hubbert NL, et al., Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69: 3959-3963.
76. Moore RA, Nicholls PK, Santos EB, et al., Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination. J Gen Virol 2002; 83: 2299-2301.
77. Lin YL, Borenstein LA, Selvakumar R, et al., Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology 1992; 187: 612-619.
78. Harvey SB, Cladel NM, Budgeon LR, et al., Rabbit genital tissue is susceptible to infection by rabbit oral papillomavirus: an animal model for a genital tissue targeting papillomavirus. J Virol 1998; 72: 5239-5244.
79. Wilgenburg BJ, Budgeon LR, Lang CM, et al., Characterization of immune responses during regression of rabbit oral papillomavirus infections. Comp Med 2005; 55: 431-439.
80. Ingle A, Ghim S, Joh J, et al., Novel laboratory mouse papillomavirus (MusPV) infection. Vet Pathol 2011; 48: 500-505.
81. Schulz E, Gottschling M, Ulrich RG, et al., Isolation of three novel rat and mouse papillomaviruses and their genomic characterization. PLoS One 2012; 7: e47164.
82. Brandsma JL,. The cottontail rabbit papillomavirus model of high-risk HPV-induced disease. Methods Mol Med 2005; 119: 217-235.
83. Amella CA, Lofgren LA, Ronn AM, et al., Latent infection induced with cottontail rabbit papillomavirus. A model for human papillomavirus latency. Am J Pathol 1994; 144: 1167-1171.
84. Brandsma JL, Xiao W,. Infectious virus replication in papillomas induced by molecularly cloned cottontail rabbit papillomavirus DNA. J Virol 1993; 67: 567-571.
85. Meyers C, Harry J, Lin YL, et al., Identification of three transforming proteins encoded by cottontail rabbit papillomavirus. J Virol 1992; 66: 1655-1664.
86. Christensen ND, Han R, Kreider JW,. Cottontail rabbit papillomavirus (CRPV). In Persistent Viral Infections, Ahmed R, Chen I, (eds). Wiley: Chichester, UK; 2000; 485-502.
87. Mejia AF, Culp TD, Cladel NM, et al., Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles. J Virol 2006; 80: 12393-12397.
88. Wu X, Xiao W, Brandsma JL,. Papilloma formation by cottontail rabbit papillomavirus requires E1 and E2 regulatory genes in addition to E6 and E7 transforming genes. J Virol 1994; 68: 6097-6102.
89. Schmitt A, Rochat A, Zeltner R, et al., The primary target cells of the high-risk cottontail rabbit papillomavirus colocalize with hair follicle stem cells. J Virol 1996; 70: 1912-1922.
90. Cladel NM, Hu J, Balogh K, et al., Wounding prior to challenge substantially improves infectivity of cottontail rabbit papillomavirus and allows for standardization of infection. J Virol Methods 2008; 148: 34-39.
91. Lange CE, Favrot C,. Canine papillomaviruses. Vet Clin N Am Small Animal Pract 2011; 41: 1183-1195.
92. Jahan-Parwar B, Chhetri DK, Hart S, et al., Development of a canine model for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 2003; 112: 1011-1013.
93. Wilgenburg BJ, Budgeon LR, Lang CM, et al., Characterization of immune responses during regression of rabbit oral papillomavirus infections. Comp Med 2005; 55: 431-439.
94. Peh WL, Middleton K, Christensen N, et al., Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol 2002; 76: 10401-10416.
95. Maglennon GA, McIntosh PB, Doorbar J,. Immunosuppression facilitates the reactivation of latent papillomavirus infections. J Virol 2014; 88: 710-716.
96. Maglennon GA, McIntosh P, Doorbar J,. Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 2011; 414: 153-163.
97. Iwasaki T, Maeda H, Kameyama Y, et al., Presence of a novel hamster oral papillomavirus in dysplastic lesions of hamster lingual mucosa induced by application of dimethylbenzanthracene and excisional wounding: molecular cloning and complete nucleotide sequence. J Gen Virol 1997; 78: 1087-1093.
98. Schulz E, Gottschling M, Wibbelt G, et al., Isolation and genomic characterization of the first Norway rat (Rattus norvegicus) papillomavirus and its phylogenetic position within Pipapillomavirus, primarily infecting rodents. J Gen Virol 2009; 90: 2609-2614.
99. Nafz J, Kohler A, Ohnesorge M, et al., Persistence of Mastomys natalensis papillomavirus in multiple organs identifies novel targets for infection. J Gen Virol 2007; 88: 2670-2678.
100. Vinzon SE, Braspenning-Wesch I, Muller M, et al., Protective vaccination against papillomavirus-induced skin tumors under immunocompetent and immunosuppressive conditions: a preclinical study using a natural outbred animal model. PLoS Pathog 2014; 10: e1003924.
101. Maeda H, Kubo K, Sugita Y, et al., DNA vaccine against hamster oral papillomavirus-associated oral cancer. J Int Med Res 2005; 33: 647-653.
102. Ingle A, Ghim S, Joh J, et al., Novel mouse papillomavirus (MusPV) infection. Vet Pathol 2011; 48: 500-505.
103. Joh J, Jenson AB, King W, et al., Genomic analysis of the first laboratory mouse papillomavirus. J Gen Virol 2011; 92: 692-698.
104. Borgogna C, Landini MM, Lanfredini S, et al., Characterization of skin lesions induced by skin-tropic α- and β-papillomaviruses in a patient with epidermodysplasia verruciformis. Br J Dermatol 2014; 171: 1550-1554.
105. Borgogna C, Lanfredini S, Peretti A, et al., Improved detection reveals active β-papillomavirus infection in skin lesions from kidney transplant recipients. Mod Pathol 2014; 27: 1101-1115.
106. Bottalico D, Chen Z, Dunne A, et al., The oral cavity contains abundant known and novel human papillomaviruses from the Betapapillomavirus and Gammapapillomavirus genera. J Infect Dis 2011; 204: 787-792.
107. Cladel NM, Budgeon LR, Balogh KK, et al., A novel pre-clinical murine model to study the life cycle and progression of cervical and anal papillomavirus infections. PLoS One 2015; 10: e0120128.
108. Cladel NM, Budgeon LR, Cooper TK, et al., Secondary infections, expanded tissue tropism, and evidence for malignant potential in immunocompromised mice infected with Mus musculus papillomavirus 1 DNA and virus. J Virol 2013; 87: 9391-9395.
109. Hu J, Budgeon LR, Cladel NM, et al., Tracking vaginal, anal and oral infection in a mouse papillomavirus infection model. J Gen Virol 2015; DOI: 10.1099/jgv.0.000295.
110. Handisurya A, Day PM, Thompson CD, et al., Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1. PLoS Pathog 2014; 10: e1004314.
111. Sundberg JP, Stearns TM, Joh J, et al., Immune status, strain background, and anatomic site of inoculation affect mouse papillomavirus (MmuPV1) induction of exophytic papillomas or endophytic trichoblastomas. PLoS One 2014; 9: e113582.
112. Van Doorslaer K, Bernard HU, Chen Z, et al., Papillomaviruses: evolution, Linnaean taxonomy and current nomenclature. Trends Microbiol 2010; 19: 49-50; author reply 50-41.
113. Shah SD, Doorbar J, Goldstein RA,. Analysis of host-parasite incongruence in papillomavirus evolution using importance sampling. Mol Biol Evolut 2010; 27: 1301-1314.
114. Schafer K, Neumann J, Waterboer T, et al., Serological markers for papillomavirus infection and skin tumour development in the rodent model Mastomys coucha. J Gen Virol 2011; 92: 383-394.
115. Hufbauer M, Biddle A, Borgogna C, et al., Expression of β-papillomavirus oncogenes increases the number of keratinocytes with stem cell-like properties. J Virol 2013; 87: 12158-12165.
116. Giampieri S, Storey A,. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. Br J Cancer 2004; 90: 2203-2209.
117. Viarisio D, Mueller-Decker K, Kloz U, et al., E6 and E7 from β-HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog 2011; 7: e1002125.
118. Pfefferle R, Marcuzzi GP, Akgul B, et al., The human papillomavirus type 8 E2 protein induces skin tumors in transgenic mice. J Invest Dermatol 2008; 128: 2310-2315.
119. Marcuzzi GP, Hufbauer M, Kasper HU, et al., Spontaneous tumour development in human papillomavirus type 8 E6 transgenic mice and rapid induction by UV-light exposure and wounding. J Gen Virol 2009; 90: 2855-2864.
120. Nonnenmacher M, Salmon J, Jacob Y, et al., Cottontail rabbit papillomavirus E8 protein is essential for wart formation and provides new insights into viral pathogenesis. J Virol 2006; 80: 4890-4900.
121. Tarzi MD, Jenner M, Hattotuwa K, et al., Sporadic case of warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis syndrome. J Allergy Clin Immunol 2005; 116: 1101-1105.
122. Gewirtzman A, Bartlett B, Tyring S,. Epidermodysplasia verruciformis and human papillomavirus. Curr Opin Infect Dis 2008; 21: 141-146.
123. Lazarczyk M, Dalard C, Hayder M, et al., EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation. PLoS One 2012; 7: e39995.
124. Crequer A, Troeger A, Patin E, et al., Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest 2012; 122: 3239-3247.
125. Crequer A, Picard C, Patin E, et al., Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. PLoS One 2012; 7: e44010.
126. Daftarian PM, Mansour M, Pohajdak B, et al., Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax-encapsulated CTL/T helper peptides. J Transl Med 2007; 5: 26.
127. Feng Q, Wei H, Morihara J, et al., Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol 2012; 127: 412-419.
128. Li B, Wang X, Zhou F, et al., Up-regulated expression of Sp1 protein coincident with a viral protein in human and mouse differentiating keratinocytes may act as a cell differentiation marker. Different Res Biol Divers 2008; 76: 1068-1080.
129. Kines RC, Thompson CD, Lowy DR, et al., The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci USA 2009; 106: 20458-20463.
130. + T cell responses. J Clin Invest 2012; 122: 4606-4620.
131. Buck CB, Thompson CD, Pang YY, et al., Maturation of papillomavirus capsids. J Virol 2005; 79: 2839-2846.
132. Buck CB, Pastrana DV, Lowy DR, et al., Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med 2005; 119: 445-462.
133. Buck CB, Pastrana DV, Lowy DR, et al., Efficient intracellular assembly of papillomaviral vectors. J Virol 2004; 78: 751-757.
134. Wilson R, Laimins LA,. Differentiation of HPV-containing cells using organotypic 'raft' culture or methylcellulose. Methods Mol Med 2005; 119: 157-169.
135. Griffin H, Soneji Y, Van Baars R, et al., Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM. Mod Pathol 2015; 28: 977-993.